Adefovir dipivoxil

Adefovir dipivoxil is an orally active adenosine analog and Adefovir prodrug. Adefovir dipivoxil inhibits DNA synthesis, activates the ATR signaling pathway, and disrupts the KCTD12-CDK1 interaction. Adefovir dipivoxil has antiviral activity against PRV, HBV, and orthopoxviruses. Adefovir dipivoxil has inhibitory effects on both lamivudine-resistant and wild-type strains. Adefovir dipivoxil has antitumor activity against lung and colon cancer[1][2][3][4][5][6][7][8][9][10][11].

Product Specifications

CAS Number

[142340-99-6]

Product Name Alternative

GS 0840

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

ATM/ATR; CDK; DNA/RNA Synthesis; HBV; HSV; Orthopoxvirus

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; PI3K/Akt/mTOR

Applications

COVID-19-anti-virus

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/Adefovir-dipivoxil.html

Purity

99.03

Solubility

DMSO : ≥ 100 mg/mL|H2O : 0.67 mg/mL (ultrasonic)

Smiles

NC1=C2N=CN(CCOCP(OCOC(C(C)(C)C)=O)(OCOC(C(C)(C)C)=O)=O)C2=NC=N1

Molecular Formula

C20H32N5O8P

Molecular Weight

501.47

Precautions

H302, H315, H319, H335

References & Citations

[1]Noble S, et al. Adefovir dipivoxil. Drugs. 1999;58 (3) :479-489.|[2]Buti M, et al. Adefovir dipivoxil. Drugs Today (Barc) . 2003;39 (2) :127-135.|[3]Mark N Prichard, et al. Orthopoxvirus targets for the development of antiviral therapies. Curr Drug Targets Infect Disord. 2005 Mar;5 (1) :17-28. |[4]Patel A, et al. Adefovir dipivoxil induces DNA replication stress and augments ATR inhibitor-related cytotoxicity. Int J Cancer. 2020 Sep 1;147 (5) :1474-1484.|[5]Maeng HJ, et al. Effects of 1α,25-dihydroxyvitamin D3 on transport and metabolism of adefovir dipivoxil and its metabolites in Caco-2 cells. Eur J Pharm Sci. 2012 Jun 14;46 (3) :149-66. |[6]Annaert P, et al. In vitro, ex vivo, and in situ intestinal absorption characteristics of the antiviral ester prodrug adefovir dipivoxil. J Pharm Sci. 2000 Aug;89 (8) :1054-62.|[7]Wang G, et al. Adefovir dipivoxil efficiently inhibits the proliferation of pseudorabies virus in vitro and in vivo. Antiviral Res. 2021 Feb;186:105014.|[8]Yang J, et al. Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction. Cancer Lett. 2019 Jun 1;451:79-91.|[9]Julander JG, et al. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res. 2002 Jul;55 (1) :27-40. |[10]Cundy KC, et al. Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs. J Pharm Sci. 1997 Dec;86 (12) :1334-8.|[11]Qaqish RB, et al. Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection. Clin Ther. 2003 Dec;25 (12) :3084-99.